Australia's Sirtex expects approval for Chinese buyout

SYDNEY, June 15 (Reuters) - Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the United States despite diplomatic tensions with China.